



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : P Laltlanzova, Asst Drugs Inspector (F and D)
CMO Office,
Lawngtlai District- 796891, Mizoram
- Serial No. and date of Inspector's memorandum : 1/061/IPA-LTI/III-25, 11-AUG-2025
- Number of Sample : NIL
- Date of receipt : 03-SEP-2025
- Names of drugs purporting to be contained in the sample : Salbutamol Sulphate Tab IP 2 mg (Asthalin-2)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0843	GUW/LS/2025-26/840	C130359	Mar-2023 Feb-2026	NA	CIPLA LTD, Plot No. 27, Jharmajari, Baddi (H.P.) 173 205

- Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

- Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 29-Sep-2025 To 29-Sep-2025

COMPOSITION : Each uncoated tablet contains:
Salbutamol Sulphate IP eq. to Salbutamol 2 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, round shaped, flat, break line on one surface and embossed "A2" on other surface, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Salbutamol Sulphate.	NA
3	Average weight	0.1121 g	NA
4	Disintegration	Complies. (Time taken for disintegration 01 minute 02 seconds)	NMT 15 minutes

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
-------	-----------------	-------	-------	------------	--------	--------------------

1	Salbutamol Sulphate IP equivalent to Salbutamol	1.85 mg/Tablet	2 mg/Tablet	92.5	90 % to 110 %	I.P. 2022
---	---	----------------	-------------	------	---------------	-----------

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 30-OCT-2025

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

----- END OF REPORT -----



1	Salbutamol Sulphate IP equivalent to Salbutamol	1.85 mg/Tablet	2 mg/Tablet	92.5	90 % to 110 %	I.P. 2022
---	---	----------------	-------------	------	---------------	-----------

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 30-OCT-2025

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

----- END OF REPORT -----

